The shared 199 transcriptional data set was investigated in the Porto Cohort of prostate cancer patients, where patients are either categorised as “Cases”, those that developed BCR, or “Control”, those that did not develop BCR [43]. This evidence concerns the gene BCR and prostate cancer.